Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.01 per share
-
Shares outstanding
-
46,239,275
-
Total 13F shares
-
6,837,224
-
Share change
-
+1,813,183
-
Total reported value
-
$254,474,000
-
Price per share
-
$37.21
-
Number of holders
-
41
-
Value change
-
+$69,986,832
-
Number of buys
-
25
-
Number of sells
-
13
Institutional Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q4 2017
As of 31 Dec 2017,
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) was held by
41 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,837,224 shares.
The largest 10 holders included
MENORA MIVTACHIM HOLDINGS LTD., ProQuest Associates IV LLC, Consonance Capital Management LP, FMR LLC, WELLINGTON MANAGEMENT GROUP LLP, MEITAV DASH INVESTMENTS LTD, HIGHLINE CAPITAL MANAGEMENT, L.P., CREDIT SUISSE AG/, PERCEPTIVE ADVISORS LLC, and DSAM Partners (London) Ltd.
This page lists
41
institutional shareholders reporting positions in this security
for the Q4 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.